Response-Adapted Treatment with Nivolumab and Brentuximab Vedotin (BV) in Children, Adolescents and Young Adults (CAYA) with Relapsed/Refractory Classical Hodgkin Lymphoma (R/R cHL): CheckMate 744 Subgroup Analyses

MLA

Peter D. Cole, et al. “Response-Adapted Treatment with Nivolumab and Brentuximab Vedotin (BV) in Children, Adolescents and Young Adults (CAYA) with Relapsed/Refractory Classical Hodgkin Lymphoma (R/R CHL): CheckMate 744 Subgroup Analyses.” Clinical Lymphoma Myeloma and Leukemia, vol. 19, Sept. 2019, p. S307. EBSCOhost, https://doi.org/10.1016/j.clml.2019.07.271.

APA

Peter D. Cole, Gérard Michel, Salvatore Buffardi, Alberto Garaventa, Stephen Francis, Richard A. Drachtman, Thomas Manley, Paul Harker-Murray, Thierry Leblanc, Laurence Brugières, Kasey J. Leger, Mariana Sacchi, Maurizio Mascarin, C Mauz-Körholz, Stephen Daw, Auke Beishuizen, Kara M. Kelly, & Stacy Cooper. (2019). Response-Adapted Treatment with Nivolumab and Brentuximab Vedotin (BV) in Children, Adolescents and Young Adults (CAYA) with Relapsed/Refractory Classical Hodgkin Lymphoma (R/R cHL): CheckMate 744 Subgroup Analyses. Clinical Lymphoma Myeloma and Leukemia, 19, S307. https://doi.org/10.1016/j.clml.2019.07.271

Chicago

Peter D. Cole, Gérard Michel, Salvatore Buffardi, Alberto Garaventa, Stephen Francis, Richard A. Drachtman, Thomas Manley, et al. 2019. “Response-Adapted Treatment with Nivolumab and Brentuximab Vedotin (BV) in Children, Adolescents and Young Adults (CAYA) with Relapsed/Refractory Classical Hodgkin Lymphoma (R/R CHL): CheckMate 744 Subgroup Analyses.” Clinical Lymphoma Myeloma and Leukemia 19 (September): S307. doi:10.1016/j.clml.2019.07.271.